Substrate of 2D6. In major parts not metabolised. No data pointing to CYP-induction or MI complex formation. Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea and obstipation motivates vigilance against insufficient intake of food, especially of carbohydrate.

(To be edited, initial data ST OCT 04) ACE- inhibitor. 75% excreted in urine of which 50% is unchanged substance and the rest captoprilcystein and disulfide derivatives. Substrate of CYP 2D6. South African list: use with care. French list: authorized.

Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea and obstipation.

Uneventful use reported in 3 patients with acute porphyria.